These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 19389880)

  • 1. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.
    Keilholz U; Letsch A; Busse A; Asemissen AM; Bauer S; Blau IW; Hofmann WK; Uharek L; Thiel E; Scheibenbogen C
    Blood; 2009 Jun; 113(26):6541-8. PubMed ID: 19389880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
    Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
    Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.
    Ochsenreither S; Fusi A; Geikowski A; Stather D; Busse A; Stroux A; Letsch A; Keilholz U
    Cancer Immunol Immunother; 2012 Mar; 61(3):313-22. PubMed ID: 21898091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
    Kitawaki T; Kadowaki N; Kondo T; Ishikawa T; Ichinohe T; Teramukai S; Fukushima M; Kasai Y; Maekawa T; Uchiyama T
    Am J Hematol; 2008 Apr; 83(4):315-7. PubMed ID: 18081032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia.
    Kawakami M; Oka Y; Tsuboi A; Harada Y; Elisseeva OA; Furukawa Y; Tsukaguchi M; Shirakata T; Nishida S; Nakajima H; Morita S; Sakamoto J; Kawase I; Oji Y; Sugiyama H
    Int J Hematol; 2007 Jun; 85(5):426-9. PubMed ID: 17562620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
    Rezvani K; Yong AS; Mielke S; Jafarpour B; Savani BN; Le RQ; Eniafe R; Musse L; Boss C; Kurlander R; Barrett AJ
    Haematologica; 2011 Mar; 96(3):432-40. PubMed ID: 21134985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
    Maslak PG; Dao T; Krug LM; Chanel S; Korontsvit T; Zakhaleva V; Zhang R; Wolchok JD; Yuan J; Pinilla-Ibarz J; Berman E; Weiss M; Jurcic J; Frattini MG; Scheinberg DA
    Blood; 2010 Jul; 116(2):171-9. PubMed ID: 20400682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
    Tsuboi A; Oka Y; Nakajima H; Fukuda Y; Elisseeva OA; Yoshihara S; Hosen N; Ogata A; Kito K; Fujiki F; Nishida S; Shirakata T; Ohno S; Yasukawa M; Oji Y; Kawakami M; Morita S; Sakamoto J; Udaka K; Kawase I; Sugiyama H
    Int J Hematol; 2007 Dec; 86(5):414-7. PubMed ID: 18192109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
    Ohno S; Takano F; Ohta Y; Kyo S; Myojo S; Dohi S; Sugiyama H; Ohta T; Inoue M
    Anticancer Res; 2011 Jul; 31(7):2447-52. PubMed ID: 21873158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
    Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
    Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
    Van Tendeloo VF; Van de Velde A; Van Driessche A; Cools N; Anguille S; Ladell K; Gostick E; Vermeulen K; Pieters K; Nijs G; Stein B; Smits EL; Schroyens WA; Gadisseur AP; Vrelust I; Jorens PG; Goossens H; de Vries IJ; Price DA; Oji Y; Oka Y; Sugiyama H; Berneman ZN
    Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13824-9. PubMed ID: 20631300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
    Nakae Y; Oka Y; Fujiki F; Morimoto S; Kamiya T; Takashima S; Nakata J; Nishida S; Nakajima H; Hosen N; Tsuboi A; Kyo T; Oji Y; Mizuguchi K; Kumanogoh A; Sugiyama H
    Cancer Immunol Immunother; 2015 Jul; 64(7):791-804. PubMed ID: 25835542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [WT1 peptide-based immunotherapy].
    Sugiyama H
    Nihon Rinsho; 2005 Jun; 63(6):1101-9. PubMed ID: 15948398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
    Maslak PG; Dao T; Bernal Y; Chanel SM; Zhang R; Frattini M; Rosenblat T; Jurcic JG; Brentjens RJ; Arcila ME; Rampal R; Park JH; Douer D; Katz L; Sarlis N; Tallman MS; Scheinberg DA
    Blood Adv; 2018 Feb; 2(3):224-234. PubMed ID: 29386195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
    Oka Y; Tsuboi A; Murakami M; Hirai M; Tominaga N; Nakajima H; Elisseeva OA; Masuda T; Nakano A; Kawakami M; Oji Y; Ikegame K; Hosen N; Udaka K; Yasukawa M; Ogawa H; Kawase I; Sugiyama H
    Int J Hematol; 2003 Jul; 78(1):56-61. PubMed ID: 12894852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.
    Rezvani K; Yong AS; Mielke S; Savani BN; Musse L; Superata J; Jafarpour B; Boss C; Barrett AJ
    Blood; 2008 Jan; 111(1):236-42. PubMed ID: 17875804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
    Ohno S; Okuyama R; Aruga A; Sugiyama H; Yamamoto M
    Anticancer Res; 2012 Jun; 32(6):2263-9. PubMed ID: 22641661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.
    Bergmann L; Miething C; Maurer U; Brieger J; Karakas T; Weidmann E; Hoelzer D
    Blood; 1997 Aug; 90(3):1217-25. PubMed ID: 9242555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
    Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
    Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.
    Krug LM; Dao T; Brown AB; Maslak P; Travis W; Bekele S; Korontsvit T; Zakhaleva V; Wolchok J; Yuan J; Li H; Tyson L; Scheinberg DA
    Cancer Immunol Immunother; 2010 Oct; 59(10):1467-79. PubMed ID: 20532500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.